Practical management of tyrosine kinase inhibitor-associated side effects in GIST.
about
European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemiaOptimizing adherence to adjuvant imatinib in gastrointestinal stromal tumor.Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: a randomized controlled open-label trial.Alternative schedules or integration strategies to maximise treatment duration with sunitinib in patients with gastrointestinal stromal tumours.Imatinib-induced liver cirrhosis in a patient with advanced gastrointestinal stroma tumor (GIST).Adjuvant therapy for high-risk gastrointestinal stromal tumour: considerations for optimal management.Prediction of the likelihood of drug interactions with kinase inhibitors based on in vitro and computational studies.Fluid retention associated with imatinib treatment in patients with gastrointestinal stromal tumor: quantitative radiologic assessment and implications for managementA one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung diseaseTreating medullary thyroid cancer in the age of targeted therapy.Management of imatinib-associated skin rash in a patient with metastatic gastrointestinal stromal tumor: a case report.Digestive tract hemorrhage due to complications with gastrointestinal stromal tumor treated with sunitinib: A case report.Surgical treatment of gastric gastrointestinal stromal tumorOptimizing tyrosine kinase inhibitor therapy in gastrointestinal stromal tumors: exploring the benefits of continuous kinase suppression.Clinical implications of repeated drug monitoring of imatinib in patients with metastatic gastrointestinal stromal tumour.Safety profiles of erlotinib therapy in patients with advanced non-small-cell lung cancer.Tumor control versus adverse events with targeted anticancer therapies.Dose optimization of tyrosine kinase inhibitors to improve outcomes in GIST.What the emergency radiologist needs to know about treatment-related complications from conventional chemotherapy and newer molecular targeted agents.Long-term efficacy of imatinib for treatment of metastatic GIST.Imatinib, dasatinib and nilotinib: a review of adverse cutaneous reactions with emphasis on our clinical experience.The benefit of using CT-perfusion imaging for reliable response monitoring in patients with gastrointestinal stromal tumor (GIST) undergoing treatment with novel targeted agents.A safety evaluation of imatinib mesylate in the treatment of gastrointestinal stromal tumor.Drug-induced hepatotoxicity in cancer patients - implication for treatment.Can therapeutic drug monitoring increase the safety of Imatinib in GIST patients?Incorporation of adjuvant therapy into the multimodality management of gastrointestinal stromal tumors of the stomach in the United States.Leukocyte trafficking is not affected by multikinase inhibitors sunitinib or sorafenib in mice.Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor.Prolonging Gastrointestinal-Stromal-Tumor-free life, an optimal suggestion of imatinib intervention ahead of operationImatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib
P2860
Q26749324-9A29F36A-94C8-4EFE-909E-18D1C15C6B44Q33885999-99FE7CC6-26AE-418E-9198-111A014FC60FQ34083140-6D0E2122-E9A3-4796-8279-5F97DE8661F3Q34141825-86382D78-2670-4AB9-951B-3ED73FAE6816Q34276167-8A854821-354F-430C-85E9-9A67FA5646F6Q34300784-A26724AE-038C-4F52-BE94-3AD0D983C7D1Q35115436-43A39354-897D-4F1C-9E68-3EE6677FE5E6Q35140171-4B2668FA-2CC3-48C0-ACD5-C2C1D7E90891Q35489187-342515E3-7E40-4F82-9627-017775286134Q35509932-895B6576-FDC3-4993-BA6E-E11B6C3B03CFQ36541788-39027EEA-BA26-445E-937E-2C28F065846EQ36611473-6402DF23-0E0B-491B-8916-0332B6BD0277Q36770203-939AFBE0-4E58-4CD0-A267-C5112652D91CQ37301465-1C578822-EEA7-4D22-8723-8BD90902928BQ37504935-3E7E9950-DCD9-4B93-8E4F-A43289849D5EQ37909352-50B94548-5C78-493E-A11E-C0DAE5F431E0Q37969899-49617F9B-35D6-45E8-B4BC-EB973DE02EFDQ37988591-F8BD6DBC-2F0A-4526-B1E0-5A81AE0DEEC2Q38016741-2ABF4293-7321-4869-91B7-4D2554153224Q38090470-E67164EB-71D0-4FC3-937F-41AE62A5742DQ38101103-08A2890B-1818-444A-A748-2A1A738A6593Q38114042-C62D1D95-E38C-48E5-A032-48AE9A2B028CQ38729029-E5CFAF25-E438-4973-87AD-8021D2986748Q38845891-B787F11D-2B08-4C25-BF0F-1E9BD8D816A0Q48278939-38FA6A89-343C-4760-BD0D-89BB30ACCAD7Q50676413-63CCDB70-2827-440F-BF71-5C70E86A2C96Q51615851-01B5D2F8-AEE7-40E4-8788-3F948B8EC141Q54599564-B781A7CD-3116-4998-97B2-2853B86B6BF0Q58582206-ADAABC0F-D699-46C6-A087-FBFFDDE4777BQ58695210-77EA88A3-0DD6-41EB-B082-69CE7DD05F62
P2860
Practical management of tyrosine kinase inhibitor-associated side effects in GIST.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 31 May 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Practical management of tyrosine kinase inhibitor-associated side effects in GIST.
@en
Practical management of tyrosine kinase inhibitor-associated side effects in GIST.
@nl
type
label
Practical management of tyrosine kinase inhibitor-associated side effects in GIST.
@en
Practical management of tyrosine kinase inhibitor-associated side effects in GIST.
@nl
prefLabel
Practical management of tyrosine kinase inhibitor-associated side effects in GIST.
@en
Practical management of tyrosine kinase inhibitor-associated side effects in GIST.
@nl
P1476
Practical management of tyrosine kinase inhibitor-associated side effects in GIST
@en
P2093
Jonathan C Trent
Peter Reichardt
P356
10.1016/J.CTRV.2010.04.008
P577
2010-05-31T00:00:00Z